CASI Pharmaceuticals, Inc.
19.10%
3,965,535
1962738
G1933S101
Jan 8, 2026
Jan 9, 2026, 06:03 AM
Reporting Persons (6)
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| WEI-WU HE, Ph.D. | Individual | 19.10% | 3,965,535 | 2,130,550 | 1,834,985 |
| EMERGING TECHNOLOGY PARTNERS, LLC | Other | 5.30% | 1,097,341 | 0 | 1,097,341 |
| ETP Global Fund L.P. | Partnership | 3.70% | 753,234 | 0 | 753,234 |
| HUIYING MEMORIAL FOUNDATION | CO | 3.10% | 637,644 | 0 | 637,644 |
| ETP BIOHEALTH III FUND, L.P. | Partnership | 1.50% | 300,000 | 0 | 300,000 |
| HE Family GRAT | Other | 0.50% | 100,000 | 0 | 100,000 |
Disclosure Items (6)
Ordinary Shares
CASI Pharmaceuticals, Inc.
1701-1702, CHINA CENTRAL OFFICE TOWER 1, BEIJING, F4, 100025
As described in Item 4 below, the Reporting Persons anticipate that, if to acquire all of the 16,810,338 ordinary shares outstanding and not currently held by the Reporting Persons and 1,000,000 ordinary shares underlying pre-funded warrants (the "Publicly Held Shares") at the price of US$1.15 per ordinary share set forth in the Proposal, an aggregate amount of approximately US$20.5 million will be used. It is anticipated that the funding for the proposed transaction will be provided by a combination of debt and equity, and that Reporting Persons as existing shareholders of the Company will roll over their equity interests in the Company to the Acquisition Vehicle.
See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Ordinary Shares and percentages of the Ordinary Shares beneficially owned by each Reporting Person. The percentage used in this Schedule 13D is calculated based upon 20,555,873 Ordinary Shares outstanding as of January 8, 2026.
See rows (7) through (10) of the cover pages to this Schedule 13D for the number of Ordinary Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
See Item 4, Purpose of Transaction.
No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.
Not applicable.
The descriptions of the principal terms of the Proposal under Item 4 are incorporated herein by reference in their entirety. To the best knowledge of the Reporting Persons, except as provided herein and disclosed before, there are no other contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Persons and between any of the Reporting Persons and any other person with respect to any securities of the Company, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies, or a pledge or contingency, the occurrence of which would give another person voting power over the securities of the Company.
Exhibit A Joint Filing Agreement by and among ETP Global Fund LP, Emerging Technology Partners LLC, ETP BioHealth III Fund, LP, HE Family GRAT and Wei-Wu He, Ph.D. dated April 18, 2023. Exhibit B Non-binding Proposal Letter from Dr. Wei-Wu He to the Company's board of directors, dated January 7, 2026 Exhibit C Updated Non-binding Proposal Letter from Dr. Wei-Wu He to the Company's board of directors, dated January 9, 2026